HEARTFLOW CMO Rogers Campbell Executes 10b5‑1 Plan: Buys 12k Shares at $8.33, Sells 24k at $55, Signaling Routine Portfolio Rebalancing Amid Bull Market Surge

Insider Activity Spotlight: Rogers Campbell’s Recent Moves at HEARTFLOW Inc.

Rogers Campbell, the company’s Chief Medical Officer, executed a Rule 10b5‑1 trading plan on October 22, 2026, buying 12,329 shares at $8.33 and 5,101 shares at $2.22 before selling 23,933 shares at $55.01. The purchases occurred while the stock traded near $57, a level that has climbed 48 % year‑to‑date, giving the trades a backdrop of robust upside. Campbell’s net position after the day’s activity stands at 73,453 shares, a modest reduction from the 92,285 shares held earlier in the month.

The timing of the purchases is notable. By the end of September, Campbell’s holdings had fallen to roughly 70 % of his original block, partly due to earlier option exercise sales. The 10b5‑1 plan, established on June 16, allows the CMO to buy and sell at pre‑determined prices and dates, mitigating “insider‑trading” concerns. Yet the recent sales—almost 24 k shares—appear to be part of a broader portfolio rebalancing rather than a response to negative news. The company’s stock remains buoyant, with a 17 % monthly gain and a 52‑week high of $57.74, suggesting that the CMO is aligning his holdings with the firm’s upside trajectory rather than hedging against a downturn.

What Does This Mean for Investors?

For long‑term shareholders, Campbell’s disciplined use of a 10b5‑1 plan signals confidence in HEARTFLOW’s pipeline and valuation. The CMO’s buy‑side activity, especially at a price near the 52‑week high, underscores his belief that the company’s valuation will stay above the current level. The subsequent sell of 23,933 shares at $55.01 may appear to dilute that confidence, but the sale price is still well above the 2025 average and only 4 % below the 52‑week high. Investors can interpret this as a liquidity event that does not materially alter the strategic outlook.

From a risk perspective, the modest size of the trades relative to the company’s $4.93 bn market cap (≈ 0.5 % of outstanding shares) limits any immediate market impact. The broader insider landscape shows a mix of buying and selling across executives—most notably CEO Farquhar John C.M., who sold nearly 39 k shares in October alone. The net effect of these moves is a neutral insider net position, reinforcing the view that management’s short‑term trading is routine rather than signal‑driven.

Rogers Campbell: A Profile of a Medical Executive Trader

Examining Campbell’s transaction history reveals a consistent pattern: he leverages both stock and option holdings to manage his exposure. He frequently sells options—often at zero cost—prior to exercising them, which is typical of a 10b5‑1 participant. Over the past three months, he has alternated between buying and selling shares, with average purchase prices hovering between $8 and $19. His sales have generally occurred at premium prices (e.g., $50.15 in mid‑September, $55.01 in October). This suggests a preference for selling when the stock is strong and buying when it dips, a classic “buy low, sell high” strategy.

Moreover, Campbell’s total shares owned after the October trades (≈ 73 k) are below the peak of ~ 99 k shares held in September, indicating a gradual divestment rather than a sudden liquidation. His option activity—selling 12,329 shares at $0 cost and 5,101 shares at $0 cost in October—demonstrates a systematic approach to exercising and selling options under the plan. The pattern is consistent with an insider who seeks to diversify his portfolio while maintaining a stake in the company’s future.

Takeaway for the Market

For investors watching HEARTFLOW, Campbell’s recent trades are a reminder that executive activity can reflect routine portfolio management rather than a reaction to company fundamentals. The 10b5‑1 structure, coupled with the steady decline in his holdings, suggests a long‑term, albeit slightly reduced, confidence in the company’s growth. The stock’s continued rally and strong quarterly results support this view. While insider buying can be a positive signal, the magnitude here is modest; investors should focus on the underlying business drivers—clinical pipeline milestones, regulatory approvals, and revenue growth—to gauge the company’s trajectory.